Female genital mutilation still happening in Canada, new research finds
A recent report has revealed that female genital mutilation/cutting is still occurring in Canada. (Credit: unomat / iStock)
A recent report suggests female genital mutilation/cutting (FGM/C) is still happening in Canada.
The research, conducted by Islamic Relief Canada through interviews and an online national survey of health-care practitioners, also found girls are taken overseas to have the procedure done — a practice known as vacation cutting.
The report, which received funding from the federal Department of Women, Gender and Equality, cautions that while data on the practice is scarce in Canada, survivors have shared their experiences.
In one case, a survivor revealed her grandmother flew to Canada specifically to perform FGM/C on her.
'This report is a vital step in understanding the extent of FGM/C in Canada and addressing the gaps in support for survivors,' Reyhana Patel, director of communications and government relations at Islamic Relief Canada, said in a news release in late March.
'One of the key themes of this study is that to truly end this practice, it must be community-led.'
FGM/C is when the labia or clitoris of a girl or woman is excised, mutilated or infibulated — the removal of the vulva and its suturing — in whole or in part, for non-medical reasons.
The Criminal Code was amended in 1997 to clarify that FGM/C is a form of aggravated assault, and that removing a child from Canada to have it performed is a criminal offence.
RECOMMENDED VIDEO
Patel said the legality of the practice will not deter its occurrence in the country.
'A comprehensive, community-led approach — supported by governments, policymakers, and service providers — is essential to effectively address and prevent FGM/C in Canada,' Patel said.
Other key findings in the report include the health-care system's inability to properly address the needs of survivors, the need for a more integrated, culturally sensitive approach to health care, and the role of community leaders, including religious leaders and elders, in combating FGM/C.
'By involving communities in educational efforts and advocacy, a sustainable approach to ending the practice and supporting those impacted can be established,' Islamic Relief Canada said.
According to the World Health Organization, more than 230 million girls and women who are alive today have undergone FGM/C in 30 countries in Africa, the Middle East and Asia.
The practice is mostly carried out on young girls between infancy and age 15. In addition, four million girls are at risk of some form of the procedure annually.
Immediate complications can include severe pain, excessive bleeding, genital tissue swelling, infections, urinary problems, issues with the wound healing, injury to surrounding genital tissue, shock, and potentially death.
Long-term risks can include urinary, vaginal and menstrual problems, scar tissue, issues having sex, increased risk of childbirth complications, the need for later surgeries, and psychological problems including depression, anxiety, post-traumatic stress disorder, and low self-esteem.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
a day ago
- Business Wire
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on ' Beyond Bispecifics and ADCs: Conditionally Active Biologics.' Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs. The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky.
Yahoo
a day ago
- Yahoo
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics SEATTLE, June 10, 2025--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced Chief Business Officer Neela Patel, Ph.D., will speak at BIO 2025 on a panel on "Beyond Bispecifics and ADCs: Conditionally Active Biologics." The panel will be held on Wednesday, June 18, 2025, in Room 206AB from 10:15 to 11:15 a.m. ET during the BIO International Convention, which takes place June 16-19, at the Boston International Convention and Exhibition Center. It is open to all registered attendees. Conditionally active biologics (CABs) are an emerging class of drugs that are safer and more efficacious than existing treatments with the potential to overcome the challenges of current state-of-the-art therapies, including ADCs and bispecifics. While companies working in this field are currently focused on oncology and immunology, many of their technologies can be applied to any protein therapeutic where regulation is required to harness a biology for patient benefit. The moderator-led discussion will explore the scientific and commercial landscape for CABs, including types of conditionally active therapeutic modalities currently in research and development, the status of clinical data for these molecules, recent technological advances, and the current and future environment for financings and deals. Patel is a scientist and business development executive with more than 25 years of leadership in drug discovery and development, project and portfolio management, and pipeline development through external innovation. Prior to joining Bonum in 2022, she was part of the executive team at Good Therapeutics, where, as Chief Business Development Officer she co-led the company's acquisition by Roche and the subsequent spinout of Bonum. She will be joined by four panelists representing different perspectives on the technology's potential and challenges, including an investor, an expert in drug development from pharma and scientist executives from biotechnology companies with technologies for regulating biologic therapeutics. Alexandra Cantley, Ph.D., Partner, Polaris Partners Stephen Demerast, Ph.D., Chief Scientific Officer, Tentarix Biotherapeutics Randi Isaacs, MD, Chief Medical Officer, Werewolf Therapeutics John C. Lin, MD, Ph.D., SVP, Immuno-Oncology, Head of Bispecifics R&D, Regeneron Pharmaceuticals Moderator: Michael C. Rice, MS, MBA, SVP, Advanced Therapeutics, Lumanity About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company that uses a novel antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Bonum's most advanced program is in preclinical development. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus milestones. Bonum's unique approach takes advantage of the ability of an antibody to bind specifically and competitively to two distinct antigens – a dual-binding antibody (DBA). The technology brings the power and specificity of an antibody to therapeutic control and is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and Bluesky. View source version on Contacts Bonum Contact: Neela Patel, Therapeutics(425) 375-5369patel@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Newsweek
4 days ago
- Newsweek
FBI Working With India to Disrupt Chinese Fentanyl Network—Kash Patel
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Federal Bureau of Investigation (FBI) Director Kash Patel told podcaster Joe Rogan during a Friday episode that the agency is working with the Indian government to dismantle global fentanyl networks, which he said originate in China. Newsweek has reached out to the FBI's press office, the Indian Government's Ministry of External Affairs, and the Chinese Embassy in Washington for comment via email on Saturday. Why It Matters President Donald Trump has made combating the opioid crisis, particularly the influx of illicitfentanyl, a central focus of his administration's policies. Earlier this year, to address the sources of fentanyl trafficking, Trump imposed tariffs on imports from China, Mexico, and Canada. There are some legitimate medical uses for fentanyl. The opioid crisis has far-reaching impacts across the country. In 2024, the United States witnessed a significant decrease in opioid-related overdose deaths, dropping from 110,037 in 2023 to 80,391 in 2024, according to data from the U.S. Centers for Disease Control and Prevention (CDC). Rogan, host of The Joe Rogan Experience podcast, is one of the most-listened-to media figures, drawing an audience of roughly 11 million listeners. What To Know Patel told Rogan that when he joined the bureau, he launched a "massive enterprise" to target companies in China that manufacture "fentanyl precursors." He said that while China may not produce the drug in its final form, it supplies the key ingredients used to make fentanyl, calling the country the "root of the problem." The U.S.-China Economic and Security Review Commission, which provides recommendations to Congress, stated in an August 2021 finding that "China remains the primary country of origin for illicit fentanyl and fentanyl-related substances trafficked into the United States." Patel said during the interview with Rogan that the country has been shipping the precursors "to places like India—and I'm also doing operations in India—and they're having the Mexican cartels now make this fentanyl down in Mexico." In March, the Chinese government published a white paper laying out its purported efforts to crack down on fentanyl trade and hit back at U.S. criticism as Washington imposed tariffs over the issue. "I literally just got off the phone with the Indian government, I said: 'I need your help. This stuff's coming into your country and then they're moving it from your country because India's not consuming fentanyl...I need you and your help,'" the FBI director told Rogan. He explained the FBI is "working with the heads of their [the Indian] government, law enforcement authorities to say, 'We're going to find these companies that buy it and we're going to shut them down. We're going to sanction them; we're going to arrest them where we can. We're going to indict them in America if we can. We're going to indict them in India if we can.'" He reiterated that "this is a global problem." Patel said the Chinese Communist Party (CCP) isn't partaking in the trade for profitability reasons, but rather, "in my opinion, the CCP have used it as a directed approach because we are their their long-term game is how do I, in my opinion, kneecap the United States of America, our largest adversary?" suggesting that the drug allows them to "take out generations of young men and women." Tensions between Washington and Beijing have been high over a slew of issues, including tariff policies and national security issues. In May, federal authorities arrested 16 individuals and seized over 400 kilograms of the drug in the largest fentanyl bust in Drug Enforcement Administration (DEA) history. FBI Director Kash Patel is seen in Washington on May 8. FBI Director Kash Patel is seen in Washington on May 8. AP Photo/Jose Luis Magana What People Are Saying U.S. Treasury Secretary Scott Bessent told CNBC in mid-May: "I have a personal stake in this. There are two very close friends [who] lost children to this terrible scourge. Hundreds of thousands of Americans die every year. And I think that we saw here in Geneva the Chinese are now serious about assisting the U.S. in stopping the flow of precursor drugs." A spokesperson for the Chinese foreign ministry said in March: "Facts speak louder than words. The U.S. is spreading all kinds of false information on the fentanyl issue, smearing and scapegoating China, and hiking tariffs on Chinese imports over fentanyl." President Donald Trump wrote in an April 24 Truth Social post: "...By the way, Fentanyl continues to pour into our Country from China, through Mexico and Canada, killing hundreds of thousands of our people, and it better stop, NOW!" What Happens Next? It is unclear what the partnership looks like, but according to Patel it is ongoing.